Abstract: In order to determine the clinical outcomes of treatment with of oral Ribavirin in the patients with Crimean-Congo Hemorrhagic Fever (CCHF), we conducted this study.In this case-control survey, we compared the recovery rate and mortality rate among patients with confirmed CCHF, who were treated with oral ribavirin within the 3 days of onset of disease with the patients who were treated after this time. Eighty nine of (48.5%) of 184 cases were treated during the initial 72 h of disease. In this group 75 patients (84%) survived and 14 cases (16%) expired. Out of 95 patients who were treated after 3 days of the onset of disease, 71 cases (74.8%) survived and 24 cases (25.2%) died.The recovery rate was higher in the patients who were treated during the initial 3 days (Relative risk = 1.75; 95% confindence interval[CI] = 0.96-3.2; p = 0.06; absolute risk increased = 0.09). We conclude that oral Ribavirin is an effective treatment for patients with CCHF, especially when it is used within 72 h of the onset of disease and as soon as it is possible.